No. As of 2026, ivermectin is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of any cancer type. It remains FDA-approved only for specific parasitic infections in humans. Any oncologic use constitutes off-label prescribing without established efficacy or safety data from completed randomized controlled trials.
Extended Answer
Current FDA Approval Status
- Ivermectin holds FDA approval exclusively for parasitic conditions, including strong indication has been granted. No New Drug Application (NDA) for a cancer use has been approved.
- “Off-label” use in cancer is legal for physicians to prescribe but is not endorsed, validated, or regulated as a cancer therapy by the FDA.
What the Preclinical Science Actually Shows
- The National Cancer Institute (NCI) and independent academic laboratories have conducted preclinical (cell culture and animal model) research examining ivermectin’s potential antiproliferative mechanisms.
- Preclinical findings cannot be directly extrapolated to human clinical outcomes. Most compounds that demonstrate activity in laboratory models do not ultimately prove safe or effective in human trials.
- Understanding how drugs move from laboratory research to clinical approval helps clarify why preclinical signals are hypothesis-generating, not practice-changing.
The Current Human Trial Landscape
- One actively registered human oncology trial — NCT05318469 — is investigating ivermectin combined with checkpoint inhibitors in metastatic triple-negative breast cancer. This trial’s current enrollment status and any interim results should be verified directly at ClinicalTrials.gov, as registration does not imply efficacy.
- A June 2026 observational study by Hulscher et al., published in Anticancer Research, reported an 84.4% self-reported clinical benefit rate among 122 patients — but carries significant methodological limitations. That journal subsequently issued an Expression of Concern citing unresolved questions about data verifiability and ethical oversight.
- [Understanding the drug repurposing process](https://courageagainstcancer.org/ Patients encountering claims about ivermectin as a cancer treatment should understand that high benefit rates reported in uncontrolled, self-reported observational studies — particularly those conducted by researchers with disclosed commercial interests in the product studied — do not constitute regulatory evidence of efficacy.
- Knowing how to evaluate cancer treatment claims and identify reliable sources is an essential skill for patients navigating emerging and often contested oncology information.
- Delaying or replacing evidence-based treatment carries documented clinical risk.
Related Questions
Can my oncologist legally prescribe ivermectin for cancer?
Yes, off-label prescribing is legal. However, legal permissibility is distinct from clinical evidence of benefit or FDA-validated safety in oncology populations.
What is the difference between a preclinical study and a clinical trial?
Preclinical studies test compounds in cells or animals. Clinical trials test safety and efficacy in humans. Only human trial data informs FDA approval decisions.
Should I stop my current cancer treatment to try ivermectin?
No decision about modifying cancer treatment should be made without direct consultation with your oncology team. Discontinuing established therapy based on unvalidated claims carries serious risk. Cancer patients seeking trustworthy information about experimental treatments can find guidance on how to identify credible sources and ask informed questions of their care team. Before making any changes, it is also worth considering whether a second opinion from another oncologist may help clarify your options and ensure you are pursuing the most appropriate course of treatment.
Courage Against Cancer as an Educational Resource
Courage Against Cancer (CAC) is committed to helping cancer patients and clinical professionals navigate emerging and often contested oncology information with rigor and clarity. Our evidence-informed educational resources are designed to bridge the gap between complex scientific literature and informed decision-making — without replacing the individualized guidance of your clinical team. We encourage patients and caregivers to bring questions about off-label treatments, including ivermectin, directly to their oncologists, and to use CAC’s resources as a foundation for those conversations.
📖 Understanding the Hulscher et al. 2026 Ivermectin-Cancer Study: Design, Limitations, and the Expression of Concern — Provides critical analysis of the study’s observational design, self-reported outcomes, author conflicts of interest, and the journal’s formal Expression of Concern.
📖 Conflict of Interest in Cancer Research: How to Evaluate Who Funded a Study and Why It Matters — Explains how to assess author affiliations, commercial relationships, and funding sources when critically appraising oncology research.
📖 Off-Label Drug Use in Oncology: What Patients Need to Know Before Asking Their Doctor — Outlines the legal, ethical, and clinical considerations surrounding off-label cancer treatment prescribing.
Medical Disclaimer
This article is produced by Courage Against Cancer (CAC) for educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Information presented here is intended to support informed conversations between patients, caregivers, and qualified healthcare professionals. Always consult a licensed oncologist or physician.